Showing results (191-200 of 302) with videos related to

Sort By:
Pageof 31
European Radiology|October 19, 2021
Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapyYoshifumi Noda, Nisanard Pisuchpen, Nathaniel D Mercaldo, et al.
Annals of Surgery|September 13, 2012
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?Ioannis T Konstantinidis, Andrew L Warshaw, Jill N Allen, et al.
Cancer|May 4, 2011
Phase 1/2 study of everolimus in advanced hepatocellular carcinomaAndrew X Zhu, Thomas A Abrams, Rebecca Miksad, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 3, 2022
Associations of patient-reported care satisfaction with symptom burden and healthcare use in hospitalized patients with cancerCarolyn L Qian, Emilia R Kaslow-Zieve, Chinenye C Azoba, et al.
Investigational New Drugs|April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patientsDouglas A Rubinson, Howard S Hochster, David P Ryan, et al.
Investigational New Drugs|July 13, 2019
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinomaMarcus Noel, Eileen M O'Reilly, Brian M Wolpin, et al.
Practical Radiation Oncology|November 27, 2014
Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancerKristina Mirabeau-Beale, Theodore S Hong, Andrzej Niemierko, et al.
Annals of Surgical Oncology|December 25, 2019
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic CholangiocarcinomaAlicia C Smart, Lipika Goyal, Nora Horick, et al.
The Oncologist|February 14, 2019
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive ChemoradiotherapyDevarati Mitra, Nora K Horick, Diane G Brackett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomasJohn V Heymach, Jayesh Desai, Judith Manola, et al.
Pageof 31